Coverage with Evidence Development: Application to pharmaceutical reimbursement decisions

证据开发的覆盖范围：在药品报销决策中的应用

• 批准号: FT0990797
• 负责人: Prof Elizabeth (Libby) Roughead
• 金额: $ 56.26万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: ARC Future Fellowships
• 财政年份: 2010
• 资助国家: 澳大利亚
• 起止时间: 2010-03-15 至 2014-06-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/FT0990797
• 关键词: Coverage; Evidence; Development; Application; pharmaceutical

Some new medicines produce only a small improvement in health but have considerable costs. When these medicines are trialled on only small numbers of people, uncertainty results about the value of the medicine, which can create problems for decision makers. Funding medicines where there is uncertainty may lead to harm when medicines are later found to be unsafe, or waste millions of dollars when they are overpriced relative to effectiveness. Not funding medicines may disadvantage patients in whom the medicines are effective. Methods to enable access to medicines while reducing uncertainty will offer significant benefit to patients, clinicians and taxpayers.

有些新药对健康状况的改善不大，但成本却相当高。当这些药物只在少数人身上试用时，药物的价值就会产生不确定性，这会给决策者带来问题。 在不确定的情况下为药物供资可能会在药物后来被发现不安全时造成伤害，或者在药物相对于有效性定价过高时浪费数百万美元。不为药物提供资金可能会使药物有效的患者处于不利地位。在减少不确定性的同时使人们能够获得药物的方法将为患者、临床医生和纳税人带来重大利益。